Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell transplantation (HCT). This study aimed to determine a blood biomarker signature early post-HCT that identifies patients at high risk for VOD/SOS. A set of 23 plasma biomarkers, selected from the VOD/SOS literature, was measured on days 0, 7, and 14 after myeloablative HCT using blood samples from patients enrolled in the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1202. Eligible cases were diagnosed with VOD/SOS in BMT CTN 1202 using the Baltimore criteria. Controls (without VOD/SOS) were matched to cases for conditioning regimen and age. Significant biomarkers were identified using the Bonferroni-adjusted Wilcoxon rank-sum test (P ≤ .002). Thirty-three patients with mild or severe VOD/SOS were identified (cases) and matched to 107 controls. Two, 8, and 5 biomarkers measured from the plasma of these patients were significantly associated with the development of VOD/SOS at days 0, 7, and 14, respectively, with the strongest associations on days 7 and 14. Biomarker associations were stronger for severe VOD/SOS risk and were stronger prognostic markers for VOD/SOS cases occurring within 28 days of HCT. Hyaluronan was most strongly associated with VOD/SOS risk, with an area under the receiver operating characteristic curve (AUC) of .81 on day 7 and .79 on day 14. Multivariate models of up to 5 biomarkers generated AUCs ranging from .82 to .85. All associations with VOD/SOS risk were independent of clinical risk factors. This study confirms previously identified biomarkers of VOD/SOS risk and identified novel prognostic biomarker signatures that identify patients at risk for VOD/SOS shortly after HCT. Multivariate analysis suggests that a combination of up to 5 of these protein biomarkers may provide a prognostic tool for identifying patients at risk for VOD/SOS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116945 | PMC |
| http://dx.doi.org/10.1016/j.jtct.2022.11.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review.
Expert Rev Hematol
January 2025
University of Münster, Münster, Germany.
Introduction: Inotuzumab ozogamicin(InO) is indicated for the treatment of adults with relapsed or refractory(R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assessed outcomes bybaseline characteristics for patients with R/R ALL treated with InO to identifywhich patients may benefit most.
Methods: In adherencewith PRISMA guidelines, searches were run in Embase and MEDLINE.
An international survey to better understand the current incidence, severity, and management of VOD/SOS.
Bone Marrow Transplant
January 2025
Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Article Synopsis
- * A significant number of respondents (67.0%) felt that early diagnosis was challenging, but many (75.8%) found the new 2023 EBMT diagnostic criteria useful and easy to apply.
- * Key risk factors for VOD/SOS included second allo-HCT, pre-existing liver disease, and prior use of antibody-drug conjugates, with varied preferences on when to start treatment.
Early defibrotide therapy and risk factors for post-transplant veno-occlusive disease/sinusoidal obstruction syndrome in childhood.
Pediatr Blood Cancer
December 2024
Department of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Article Synopsis
- Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a serious complication that can occur after hematopoietic cell transplantation (HCT), especially in pediatric patients.
- A study at Kyushu University Hospital evaluated the effects of early defibrotide (DF) therapy on children with VOD/SOS after HCT, revealing that VOD/SOS was more common in patients treated post-DF introduction, likely due to higher cases of relapsed/refactory acute lymphoblastic leukemia (ALL).
- Findings suggest that starting DF therapy early based on specific diagnostic criteria significantly lessens the severity of VOD/SOS and improves survival, although the overall incidence of VOD/SOS
Verification of the Prediction Accuracy of a Biomarker-Based Prognostic for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Cell Transplantation (HCT).
Transplant Cell Ther
October 2024
Pediatric Oncology, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Article Synopsis
- - Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication after hematopoietic cell transplantation (HCT), and early treatment can improve patient outcomes, but diagnosis is difficult due to overlapping symptoms with other issues post-transplant.
- - The study aimed to validate "VODCheck," a biomarker-based test designed to predict VOD/SOS risk using three key biomarkers: hyaluronan (HA), angiopoietin-2 (ANG-2), and thrombomodulin (TM).
- - Results showed that VODCheck accurately predicted VOD/SOS risk at multiple time points post-HCT, demonstrating its effectiveness as an independent risk predictor and providing valuable insights for better
Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation.
Ann Hematol
May 2024
Department of Central Clinical Laboratory, Osaka Metropolitan University Hospital, Osaka, Japan.
Article Synopsis
- Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication following allogeneic hematopoietic cell transplantation (allo-HCT), with a significant need for identifying high-risk patients prior to the procedure.
- A study of 252 patients found that higher serum autotaxin (ATX) levels before conditioning were linked to an increased incidence of VOD/SOS, showing that patients with elevated ATX had a 22.7% incidence compared to just 3.5% in those with normal levels.
- Elevated baseline ATX was determined to be an independent risk factor for VOD/SOS, indicating its potential as a valuable predictive marker for assessing risk in patients undergoing allo
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!